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Background: Direct hemoperfusion with polymyxin B-immobilized fiber (PMX-DHP) has been widely used for patients
with septic shock around the world, but the prognostic factors have not been fully understood. We conducted a
retrospective analysis to determine the prognostic factors in patients with septic shock who underwent PMX-DHP.
Methods: Twenty-nine patients with septic shock who underwent PMX-DHP were included in the study. The patients
were divided into groups based on survival (n = 23) and non-survival (n = 6) 28 days after PMX-DHP, and the clinical
data for the two groups before and after PMX-DHP were compared.
Results: In non-survivors, the vasopressor dependency index before PMX-DHP was significantly higher (p = 0.046), and
the leukocyte count before PMX-DHP was significantly lower (p = 0.024) than in survivors. Furthermore, base excess after
PMX-DHP was significantly lower in non-survivors (p = 0.007) than in survivors. The optimal cutoff points of the
vasopressor dependency index, leukocyte count, and base excess identified by receiver operating characteristic curves
were 0.499/mmHg, 1360/μL, and −6.4 mmol/L, respectively. And the score using these three cutoffs, termed the
prognostic score, was related to the prognosis of septic shock patients who underwent PMX-DHP (area under the
curve = 0.946).
Conclusions: The prognostic score, using three parameters which are immediately and readily available in early phase
after starting PMX-DHP, might be useful to predict the prognosis of these patients.
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Sepsis is a systemic inflammatory response syndrome in-
duced by infection [1]. Severe sepsis and septic shock affect
15 to 19 million people worldwide each year [2], mortality
rate is declining as a result of advances in treatment, but is
still 20% to 30% [3,4]. Intra-abdominal infection is a main
focus of severe sepsis and septic shock [5], and a crucial
problem in surgical critical care. The Surviving Sepsis* Correspondence: smatsu@yamaguchi-u.ac.jp
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unless otherwise stated.Campaign emphasized the importance of source control,
adequate antibiotics therapy, and hemodynamic support in
the early phase of sepsis management [6], which is termed
early goal directed therapy [7]. Antibiotic and surgical ther-
apies for source control are essential, but these approaches
cannot remove endotoxins and the endogenous mediators
already released into blood.
Polymyxin B-immobilized fiber (PMX) is a commer-
cially available column that is covalently bound to poly-
myxin B (Toraymyxin; Toray Industries, Tokyo, Japan).
Its structure prevents the elution of polymyxin B and
protects patients from nephrotoxicity and neurotoxicity
[8]. PMX is believed to mainly adsorb endotoxin, butntral. This is an Open Access article distributed under the terms of the Creative
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mide, inducing hypotension, immunosuppression, and
cytotoxicity [9], and reduces serum cytokine levels
[10,11], monocyte messenger RNA expression [12], and
the percentage of CD4+ CD25+ Forkhead box protein 3
(Foxp3)+ T cells, termed regulatory T cells in the CD4+
T cell population [13].
It is known that direct hemoperfusion with PMX
(PMX-DHP) has various effects on septic shock, and a
few studies have shown that it has an ameliorating
effect on prognosis [14]. Although a preliminary ran-
domized controlled trial showed that PMX-DHP im-
proved hemodynamic and respiratory dysfunction and
reduced 28-day mortality in patients with severe sepsis
and septic shock due to intra-abdominal infection [15], its
improvement effect on prognosis remains controversial
[16]. And two randomized controlled trials are ongoing in
France (Effects of Hemoperfusion With a Polymyxin B
Membrane in Peritonitis With Septic Shock (ABDO-
MIX); ClinicalTrials.gov identifier: NCT01222663) and
the United States (Safety and Efficacy of Polymyxin B
Hemoperfusion (PMX) for Septic Shock (EUPHRATES);
ClinicalTrials.gov identifier: NCT01046669). Before
discussing the role of PMX-DHP in the management
of patients with severe sepsis and septic shock, we
should consider the forthcoming results of these on-
going trials.
It is unclear which patients will benefit from PMX-
DHP and survive septic shock. If we could predict the
prognosis of septic shock patients who undergo PMX-
DHP, we would be able to identify the patient in danger
of death and make risk stratification for future novel
therapies. To determine the predictive factors of survival
in the early phase after starting PMX-DHP and make
clinical prediction rule for survival, we conducted a




Twenty-nine consecutive patients with septic shock who
underwent PMX-DHP between January 2006 and De-
cember 2013 in the Department of Digestive Surgery
and Surgical Oncology at Yamaguchi University Hospital
were enrolled in this retrospective study. This study was
approved by the institutional review board of Yamaguchi
University. The review board approved the waiving of
the informed consent because this study consisted of a
historical cohort.
All patients were followed up until discharge or death.
The patients were divided into groups based on survival
(n = 23) and non-survival (n = 6) 28 days after PMX-
DHP, and the clinical data for the two groups before and
after PMX-DHP were compared.Initial resuscitation
Administration of catecholamine was started to keep the
patient’s mean arterial pressure (MAP) ≥65 mmHg des-
pite adequate fluid resuscitation. We used noradrenaline
as first-choice vasopressor and added vasopressin (0.03
U/min) if needed. Dobutamine infusion was added to
vasopressor in patients with myocardial dysfunction [6].
Procedures for source control were conducted as soon
as possible, if feasible. The presumptive therapies with
broad spectrum antibiotics were started as soon as pos-
sible, and switched to definitive therapies with narrower
spectrum agents after culture results and antimicrobial
susceptibility data returned.
PMX-DHP
PMX-DHP was performed for patients with hemodynamic
instability in spite of administration of catecholamine
through a double-lumen catheter inserted in the cervical
vein or the femoral vein at a blood flow rate of 80–
100 mL/min with 20 mg/h nafamostat mesilate, as the
anticoagulant. Treatment was performed for longer than
2 h and up to 24 h because some reports have suggested
that an extended duration of treatment may be beneficial
[17]. All patients underwent one or two sessions of PMX-
DHP.
Clinical data
Clinical data were recorded, and the Acute Physiology
and Chronic Health Evaluation (APACHE II) score [18],
Sequential Organ Failure Assessment (SOFA) score [19],
and disseminated intravascular coagulation score from
the Japanese Association of Acute Medicine [20] was de-
termined at the start of PMX-DHP.
The inotropic score [21,22] is the most commonly
used index in critical care medicine for expressing
hemodynamic dysfunction and is calculated as follows (all
doses are expressed as μg/kg/min): (dopamine dose × 1) +
(dobutamine dose × 1) + (adrenaline dose × 100) + (nor-
adrenaline dose × 100) + (phenylephrine dose × 100). Be-
cause this score has different meaning for targeted arterial
pressure, we adopted the vasopressor dependency index
(VDI) [15], which was introduced in the Early Use of Poly-
myxin B Hemoperfusion in Abdominal Sepsis (EUPHAS)
trial and is calculated as the ratio of the inotropic score to
the MAP.
The uses of continuous renal replacement therapy,
antithrombin, recombinant-soluble thrombomodulin, and
intravenous immunoglobulin were recorded. Procedures for
source control included drainage for abdominal abscess.
We recorded the MAP, VDI, improvement rate of
the VDI, leukocyte count, data on arterial blood gases,
improvement rate of the PaO2/FIO2 ratio, and lactate
clearance rate 6 h after the start of PMX-DHP. Although
duration of PMX-DHP differed from patients to patients,
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pletion of that to evaluate every patient at the same point
in time and determine the prognostic factors in the early
phase after starting PMX-DHP.
Statistical analysis
Categorical variables are presented as numbers and were
analyzed by using Fisher’s exact test. Continuous variables
were compared by using the Mann–Whitney U test and
data are presented as medians and ranges. We selected the
predictive factors of 28-day survival, constructed receiver
operating characteristic (ROC) curves of each factor and
determined the area under the curve (AUC). The optimal
cutoff point for balancing the sensitivity and specificity of
each factor was identified as the point on the ROC curve
closest to the upper left-hand corner. Subsequently, we al-
located one point to each of the prognostic factor which
was worse than the respective cutoff value, and calculated
the total score of each patient, termed the prognostic
score, by adding these points. The Kaplan-Meier method
and log-rank test were performed for survival analysis of
each score. We constructed ROC curve of the prognostic
score for the prediction of 28-day survival and determined
the AUC. A p value ≤0.05 was considered statistically sig-




The demographic data before PMX-DHP are shown in
Tables 1 and 2. Of the 29 patients, 23 patients were alive
and 6 patients had died 28 days after PMX-DHP. The
proportion of cases of intra-abdominal infection was
greater in survivors than in non-survivors (p = 0.013).
We did not conduct procedures for source control in






Age (years) 67.0 (27–95) 74.5 (58–83) 0.269
Gender (male/female) 14/9 4/2 0.592
Site of infection (number
of patients)
Intra-abdominal infection 21 3 0.013
Pneumonia 1 0
unidentified source 1 1
CRBSI 0 1




Data are presented as medians (ranges).
Abbreviations: CRBSI catheter-related bloodstream infection.source, a patient with pneumonia and a patient with sys-
temic vibrio vulnificus infection. And a patient with ab-
dominal abscess after hepatectomy did not undergo
drainage because of marked bleeding tendency, and sur-
vived to discharge.
Of the 29 patients, 24 patients were treated with carba-
penem or piperacillin/tazobactam agents as initial therap-
ies. And vancomycin or daptomycin or linezolid were used
concurrently if methicillin-resistant Staphylococcus aureus
or Enterococcus species infection were possible pathogens.
There were no differences between the two groups in
use of antithrombin, recombinant soluble thrombomodu-
lin, and intravenous immunoglobulin (data not shown).
Comparison of the clinical features and laboratory data
before PMX-DHP between survivors and non-survivors
In non-survivors, the VDI before PMX-DHP was signifi-
cantly higher (p = 0.046) and the leukocyte count before
PMX-DHP was significantly lower (p = 0.024) than in
survivors (Tables 3 and 4). We were not able to evaluate
which population of leukocytes decreased in non-
survivors because differential leukocyte counts were not
consistently available. There were no other significant
differences between the two groups.
Comparison of clinical features 6 h after the start of
PMX-DHP between survivors and non-survivors
The pH and base excess (BE) of arterial blood of non-
survivors were significantly lower than those of survi-
vors (p = 0.018 and 0.007, respectively) (Table 5). The
lactate level was significantly higher in non-survivors
(p = 0.043). The VDI after PMX-DHP decreased signifi-
cantly (p = 0.0036) compared with the VDI before
PMX-DHP only in survivors (data not shown). There
was no significant difference in leukocyte count be-
tween survivors and non-survivors. And it did not
show significant changes between before- and after
PMX-DHP in both groups (data not shown). There
were no significant differences in the VDI, improve-
ment rate of the VDI, improvement rate of the PaO2/
FIO2 ratio, and lactate clearance rate.
Analysis of ROC curves
We constructed ROC curves of the VDI (Figure 1a) and
leukocyte count (Figure 1b) before PMX-DHP for the
prediction of 28-day survival and determined the AUC.
The AUC (95% CI) of the ROC curves of the VDI and
leukocyte count were 0.768 (0.514–1.000) and 0.804
(0.551–1.000), respectively. The optimal cutoff points
(sensitivity, specificity) of the VDI and leukocyte count
were 0.499/mmHg (78.3%, 83.3%) and 1360/μL (100%,
66.7%), respectively.
The BE, pH, and lactate level after PMX-DHP were sig-
nificantly correlated, and regression coefficients between






ICU admission to PMX-DHP start (min) 62 (15–2,317) 75 (20–1,170) 0.483
Number of PMX-DHP per patient (1/2) 19/4 4/2 0.363
Time per treatment (min)
1st session 325 (50–1,835) 820 (200–1,340) 0.161
2nd session 1,080 (420–1,440) 1,372 (1,330–1,414) NA
Total time of PMX-DHP (min) 360 (50–2,880) 1,330 (490–2,455) 0.091
CRRT (+/−) 14/9 5/1 0.302
Data are presented as medians (ranges).
Abbreviations: ICU intensive care unit, PMX-DHP direct hemoperfusion with polymyxin B-immobilized fiber, NA not available, CRRT continuous renal replacement therapy.
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were 0.8095, −0.5167, and −0.6373, respectively. To com-
pare the prediction abilities of these factors, we con-
structed ROC curves. Because the AUC of the ROC curve
of BE was greater than that of pH and lactate level (BE:
0.866 (95% CI 0.647–1.000), pH: 0.819 (95% CI 0.638–
0.999), lactate level: 0.772 (95% CI 0.505–1.000)), we
considered BE to be the superior prognostic factor. We
judged the optimal cutoff point of BE after PMX-DHP
to be −6.4 mmol/L, and the sensitivity and specificity at
this point were 95.7% and 83.3%, respectively (Figure 1c).
Prognostic score and 28-day survival
Subsequently, we allocated one point to each of the three
prognostic factors (VDI before PMX-DHP greater than
0.499/mmHg, leukocyte count before PMX-DHP less than
1360/μL, and BE after PMX-DHP less than −6.4 mmol/L),
and calculated the prognostic score by adding these
points. The 28-day survival rate for each score is shown
in Figure 2. All patients with a score of 0 (n = 18) were
alive after 28 days. The survival rates of patients with a
score of 1 (n = 6) and a score of 2 (n = 4) were 67% and
25%, respectively. The patient with a score of 3 (n = 1)Table 3 Comparison of the clinical features before PMX-DHP
Survivors
(n = 23)
Respiratory rate (/min) 16 (10–25)
Bladder temperature (Celsius) 36.9 (34.2–38.8)
Heart rate (/min) 105 (67–135)
MAP (mmHg) 70 (50–117)
Inotropic score 14.1 (2.3–44.7)
VDI (/mmHg) 0.195 (0.025–0.645)
APACHE II score 15 (8–26)
SOFA score 7 (2–13)
DIC score 2 (0–8)
Data are presented as medians (ranges).
Abbreviations: MAP mean arterial pressure, VDI vasopressor dependency index, APAC
failure assessment, DIC disseminated intravascular coagulation.died within 24 h after the start of PMX-DHP. There
were significant differences in survival rates between a
score of 0 and a score of 1 (p = 0.0078) and between a
score of 0 and a score of 2 (p < 0.0001). The number of
patients with a score of 3 was too small for statistical
analysis.
The ROC curve of the prognostic score for the predic-
tion of 28-day survival is shown in Figure 3. The AUC
(95% CI) was 0.946 (95% CI 0.865–1.000) and greater
than those of each three factors.
Discussion
The findings of this retrospective study suggest that the
VDI and leukocyte count before PMX-DHP and BE after
PMX-DHP may be prognostic factors, and the total
score calculated with cutoff points for these factors
could be related to the survival rate of patients with sep-
tic shock who undergo PMX-DHP. Some studies have
reported prognostic factors in these patients, including
APACHE II score [23,24], SOFA score [23], and HMGB-
1 [25]. To the best of our knowledge, this is the first re-
port suggesting that VDI and leukocyte count before













HE II acute physiology and chronic health evaluation, SOFA sequential organ






Leukocytes (/μl) 6,420 (1,370–25,220) 1,110 (430–16,540) 0.024
Ht (%) 33.3 (23.8–44.9) 34.4 (19.2–45.5) 0.957
Platelets (×104/μl) 14.3 (3.2–42.0) 8.5 (5.2–19.1) 0.053
Total bilirubin (mg/dl) 0.6 (0.4–8.2) 1.0 (0.8–2.0) 0.110
Creatinine (mg/dl) 0.98 (0.36–3.36) 1.18 (0.72–2.82) 0.132
D-dimer (μg/ ml) 11.2 (1.0–502.9) 7.8 (3.7–16.6) 0.448
C-reactive protein (mg/dl) 6.75 (0.26–27.38) 7.07 (0.34–13.05) 0.477
Arterial blood gases
pH 7.354 (7.249–7.469) 7.325 (7.208–7.404) 0.258
Base excess (mmol/l) −3.80 (−10.2–3.1) −6.10 (−8.10–1.60) 0.170
P/F (mmHg) 229 (91–525) 195 (102–395) 0.360
Lactate (mmol/l) 3.3 (0.6–8.7) 4.8 (1.7–7.8) 0.389
Data are presented as medians (ranges).
Abbreviation: P/F PaO2/FlO2 ratio.
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three factors.
The VDI, which was introduced in the EUPHAS trial
[15], is a surrogate marker of hemodynamic status express-
ing a relationship between the dose of catecholamine and
the response of MAP. There were no differences in MAP
and inotropic score in this study, whereas the VDI in non-
survivors was significantly higher than that in survivors.
This result suggests that the VDI is a more sensitive
marker of hemodynamic in patients with septic shock than
the inotropic score. Kobayashi et al. reported that early im-
provement of VDI after PMX-DHP was a prognostic factor
and a significant decrease in the VDI after PMX-DHP was
seen only in survivors [26]. Because it is impossible to
judge whether decreasing of the VDI in each patient is sig-
nificant, we need to set a cutoff point or evaluate theTable 5 Comparison of clinical features 6 h after the start of P
Survivors
(n = 23)
MAP (mmHg) 75 (45–101)
VDI (/mmHg) 0.106 (0.000–0.569)
Improvement rate of VDI (%) 39.3 (−116.9–100.0)
Leukocytes (/μl) 5,700 (1,050–31,200)
Arterial blood gas
pH 7.395 (7.305–7.458)
Base excess (mmol/l) −1.7 (−6.7–5.5)
P/F (mmHg) 267 (108–483)
Improvement rate of P/F (%) 9.0 (−44.8–228.2)
Lactate (mmol/l) 2.9 (0.8–8.8)
Lactate clearance (%) 10.0 (−83.3–61.9)
Data are presented as medians (ranges).
Abbreviations: MAP mean arterial pressure, VDI vasopressor dependency index, P/F Pimprovement rate of the VDI for prediction of prognosis.
The AUC of the ROC curve of the VDI after PMX-DHP in
our study for the prediction of 28-day survival was 0.739
(95% CI 0.544–0.934) and inferior to that before PMX-
DHP. However, the cutoff point of the VDI before PMX-
DHP determined in our study was also not sufficient for
prognostic prediction; these results indicate that the VDI
may be just one aspect of the severity of sepsis.
There were no significant differences in VDI and im-
provement rate of the VDI between the two groups 6 h
after the start of PMX-DHP in this study. We think two
main reasons for this. First, sample size was too small to
detect significance because VDI in non-survivors after
PMX-DHP tended to be higher than that in survivors
(Table 5). Second, microcirculatory dysfunction could


















Figure 1 Receiver operating characteristic (ROC) curves for the prediction of 28-day survival. (a) ROC curve of the vasopressor dependency
index (VDI). The optimal cutoff point is represented as an open circle. The area under the curve (95% confidence interval) and optimal cutoff points
(sensitivity, specificity) of the vasopressor dependency index were 0.768 (0.514–1.000) and 0.499/mmHg (78.3%, 83.3%), respectively. (b) ROC curve of
the leukocyte count. The optimal cutoff point is represented as an open circle. The area under the curve (95% confidence interval) and optimal cutoff
points (sensitivity, specificity) of the leukocyte count were 0.804 (0.551–1.000) and 1360/μL (100%, 66.7%), respectively. (c) ROC curve of base
excess (BE). The optimal cutoff point is represented as an open circle. The area under the curve (95% confidence interval) and optimal cutoff
points (sensitivity, specificity) of base excess were 0.866 (0.647–1.000) and −6.4 mmol/L (95.7%, 83.3%), respectively.
Matsukuma et al. Journal of Intensive Care  (2015) 3:13 Page 6 of 9A decreased peripheral blood leukocyte count in the
early phase of sepsis has been explained as the migration
of leukocytes to the focus of infection or some organsinduced by several cytokines, and it is an important fea-
ture for the diagnosis of sepsis [27]. Leukopenia has
been reported as a prognostic factor of sepsis in some
Figure 2 Survival rate of each group. We allocated one point to each of the three prognostic factors (vasopressor dependency index before
PMX-DHP greater than 0.499/mmHg, leukocyte count before PMX-DHP less than 1360/μL, and base excess after PMX-DHP less than −6.4 mmol/L), and
calculated the prognostic score by adding these points. All patients with a score of 0 (n= 18) were alive after 28 days, whereas the patient with a score
of 3 (n= 1) died within 24 h. The survival rates of the patients with a score of 1 (n= 6) and a score of 2 (n= 4) were 67% and 25%, respectively. There
were significant differences in survival rates between a score of 0 and a score of 1 (p = 0.0078) and between a score of 0 and a score of 2 (p < 0.0001).
Abbreviation: PMX-DHP, direct hemoperfusion with polymyxin B-immobilized fiber.
Figure 3 Receiver operating characteristic curve of the prognostic score for the prediction of 28-day survival. The area under the curve
(95% confidence interval) was 0.946 (0.865–1.000) and greater than those of each three factors.
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important in patients with septic shock who have under-
gone PMX-DHP. Unfortunately, the differential leukocyte
count was not assessed in almost half of our patients, so
it is unknown which population is especially important
for prognosis. Because leukopenia in patients with sep-
sis means that hematopoietic function cannot respond
to inflammation, immunodeficiency could develop in
these patients.
Acidemia, decreased BE, and hyperlactemia are conse-
quences of tissue hypoperfusion and imbalance of oxygen
delivery and consumption. Of these three factors, lactate
has been focused on in the past. Lactate-guided therapy
significantly reduces hospital mortality [29], and the Sur-
viving Sepsis Campaign guideline recommends normaliz-
ing the lactate level as rapidly as possible [6]. On the other
hand, Couto-Alves et al. have reported a scoring system
using BE and platelet count at presentation for prognostic
prediction in pediatric meningococcal sepsis [30]. Al-
though the lactate level was also significantly higher
among non-survivors in that study, BE was used to build a
score because of its better sensitivity. The reason why BE
was more sensitive than lactate is unknown, but this dis-
crepancy could reflect increased fixed acids by impaired
excretion that resulted from renal dysfunction or hyperca-
tabolism caused by inflammation.
In this study, the proportion of septic patients with
intra-abdominal infection was significantly higher in the
survivors. Although there was no difference between
survivors and non-survivors regarding whether proced-
ure was performed, the fact that surgical procedures
were more available for intra-abdominal infection com-
pared with other infectious sources may improve sur-
vival. In addition, PMX-DHP may be more useful for
intra-abdominal sepsis, as reflected in many studies of
PMX-DHP designed for intra-abdominal sepsis alone.
We acknowledge that this study has some limitations.
First, a small number of patients with septic shock at-
tributable to various causes were analyzed, and we could
not perform multivariate analysis because of the limited
number of patients. For this reason, these findings can-
not be generalized to the broader clinical situation
based on this study alone. Second, the effectiveness of
PMX-DHP itself is uncertain because this study was
retrospective. Third, the predictive score, which was cal-
culated by adding one point for each factor, is insuffi-
cient because the weighting of each factor was not
considered. We need to identify prognostic factors in
well-designed, prospective, randomized, controlled trials
with a large number of patients.
Conclusions
In conclusion, the VDI and leukocyte count at the start of
PMX-DHP and BE 6 h after the start of PMX-DHP arerelated to prognosis of patients with septic shock who
undergo PMX-DHP. The prognostic score using the re-
spective cutoff values of these three factors may be useful
to predict the prognosis of these patients.
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